Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CEO Samuel Kintz sold 5,000 shares of the company's stock in a transaction on Thursday, April 17th. The stock was sold at an average price of $16.42, for a total value of $82,100.00. Following the transaction, the chief executive officer now directly owns 985,392 shares in the company, valued at $16,180,136.64. This represents a 0.50 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Samuel Kintz also recently made the following trade(s):
- On Monday, March 17th, Samuel Kintz sold 12,500 shares of Enliven Therapeutics stock. The stock was sold at an average price of $20.83, for a total transaction of $260,375.00.
Enliven Therapeutics Stock Performance
ELVN stock traded down $0.09 during midday trading on Friday, hitting $18.21. 124,974 shares of the stock were exchanged, compared to its average volume of 263,317. The stock's 50-day moving average price is $19.37 and its 200-day moving average price is $22.67. The stock has a market cap of $892.36 million, a price-to-earnings ratio of -9.58 and a beta of 1.03. Enliven Therapeutics, Inc. has a fifty-two week low of $13.30 and a fifty-two week high of $30.03.
Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last released its quarterly earnings results on Thursday, March 13th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.07. The firm had revenue of $0.03 million for the quarter. Research analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright raised their price objective on shares of Enliven Therapeutics from $37.00 to $39.00 and gave the company a "buy" rating in a research note on Friday, March 21st.
Check Out Our Latest Research Report on Enliven Therapeutics
Hedge Funds Weigh In On Enliven Therapeutics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC increased its stake in shares of Enliven Therapeutics by 230.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company's stock worth $36,000 after purchasing an additional 1,114 shares in the last quarter. GAMMA Investing LLC increased its position in Enliven Therapeutics by 3,058.1% during the first quarter. GAMMA Investing LLC now owns 2,716 shares of the company's stock worth $53,000 after buying an additional 2,630 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in shares of Enliven Therapeutics in the fourth quarter worth $97,000. BNP Paribas Financial Markets purchased a new stake in shares of Enliven Therapeutics in the fourth quarter valued at $112,000. Finally, ExodusPoint Capital Management LP acquired a new stake in shares of Enliven Therapeutics during the fourth quarter valued at $200,000. Institutional investors and hedge funds own 95.08% of the company's stock.
About Enliven Therapeutics
(
Get Free Report)
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
Further Reading
Before you consider Enliven Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enliven Therapeutics wasn't on the list.
While Enliven Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
